MedTrace Logo

Study of Botulinum Toxin in Patients With Primary Hyperhidrosis

NCT00004480 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES:

I. Determine the optimal dose of botulinum toxin necessary to decrease sweating in patients with primary hyperhidrosis.

Conditions

  • Hyperhidrosis

Interventions

DRUG

botulinum toxin type A

Sponsors & Collaborators

Principal Investigators

  • Horacio Kaufmann · Icahn School of Medicine at Mount Sinai

Study Design

Purpose
TREATMENT

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004480 on ClinicalTrials.gov